Emicizumab for infants and children with haemophilia A

Affiliations

Comment

Sarina Levy-Mendelovich. Br J Haematol. 2020 Oct.

. 2020 Oct;191(2):145-146.

doi: 10.1111/bjh.16965. Epub 2020 Jul 19.

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

No abstract available

Keywords: Emicizumab; FVIII therapy; pediatric hemophilia A.

Comment on

Emicizumab treatment and monitoring in a paediatric cohort: real-world data.
Barg AA, Livnat T, Budnik I, Avishai E, Brutman-Barazani T, Tamarin I, Bashari D, Misgav M, Kenet G. Barg AA, et al. Br J Haematol. 2020 Oct;191(2):282-290. doi: 10.1111/bjh.16964. Epub 2020 Jul 12. Br J Haematol. 2020. PMID: 32656767

1. Hermans C, De Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T, et al. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia. 2011;17:383-92.
1. Leissinger CA. Advances in the clinical management of inhibitors in hemophilia A and B. Semin Hematol. 2016;53(1):20-7.
1. Ingerslev J, Sørensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol. 2011;155(2):256-62.
1. Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153-70.
1. Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood. 2018;132(1):23-30. https://doi.org/10.1182/blood-2017-09-743385.